Last $2.81 USD
Change Today -0.03 / -1.06%
Volume 2.9M
BLRX On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
Stuttgart
Tel Aviv
As of 5:20 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

biolinerx ltd-spons adr (BLRX) Snapshot

Open
$2.80
Previous Close
$2.84
Day High
$3.28
Day Low
$2.63
52 Week High
03/5/15 - $3.28
52 Week Low
11/28/14 - $1.20
Market Cap
109.9M
Average Volume 10 Days
939.5K
EPS TTM
--
Shares Outstanding
39.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOLINERX LTD-SPONS ADR (BLRX)

biolinerx ltd-spons adr (BLRX) Related Businessweek News

No Related Businessweek News Found

biolinerx ltd-spons adr (BLRX) Details

BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; and BL-9020 for the treatment of type 1 diabetes. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

43 Employees
Last Reported Date: 03/17/14
Founded in 2003

biolinerx ltd-spons adr (BLRX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biolinerx ltd-spons adr (BLRX) Key Developments

The German Federal Institute for Drugs and Medical Devices Receives Regulatory Application from BioLineRx to Approve Phase IIb Trial of BL-8040

The German Federal Institute for Drugs and Medical Devices has received regulatory applications from BioLineRx, seeking approval to start a Phase IIb trial of its clinical-stage drug candidate, BL-8040, as a new consolidation treatment for acute myeloid leukaemia. The product is used to treat acute myeloid leukaemia and other haematological indications and mobilises cancer cells from the bone marrow and may therefore sensitise these cells to chemo- and bio-based anti-cancer therapy. Without consolidation treatment aimed at destroying the remaining leukemic cells, AML is likely to return within several months of initial remission. The current principal options for AML consolidation therapy involve either several cycles of high-dose chemotherapy or stem cell transplantation. Based on positive results from ongoing phase IIa clinical trial for BL-8040, which show substantial mobilisation of AML cancer cells from the bone marrow to the peripheral blood, as well as induction of apoptosis of AML cells.

BioLineRx, Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-19-2015 09:30 AM

BioLineRx, Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-19-2015 09:30 AM. Venue: Dan Panorama Hotel, Charles Clore Park, Tel Aviv 68012, Israel. Speakers: David Malek, Vice President of Business Development.

BioLineRx, Ltd. Announces Completion of Enrollment in CE Mark Registration Trial of BCM (BL-1040)

BioLineRx, Ltd. announced that patient enrollment has been completed in Bellerophon's PRESERVATION I pivotal CE Mark registration trial of BL-1040, currently named Bioabsorbable Cardiac Matrix (BCM), a novel resorbable polymer solution for the prevention of cardiac remodeling following an acute myocardial infarction (AMI). The PRESERVATION I CE Mark registration trial is a double-blind, placebo-controlled study aimed at evaluating the safety and effectiveness of BL-1040 in the prevention of ventricular remodeling and congestive heart failure when administered following AMI. Three hundred and three AMI patients were enrolled and treated at almost 90 sites worldwide, 16 of which are in the U.S. The study, which includes a six-month follow-up period, is anticipated to be completed in mid-2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLRX:US $2.81 USD -0.03

BLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLRX.
View Industry Companies
 

Industry Analysis

BLRX

Industry Average

Valuation BLRX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLINERX LTD-SPONS ADR, please visit www.biolinerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.